Executives On The Move: Five Prime Fills Its CFO Slot, Myovant Appoints Chief Commercial Officer and Onconova Adds a CMO, R&D
Immuno-oncology treatment developer Five Prime Therapeutics hires a CFO, while Myovant Sciences, focused on women’s health and endocrine disease, appoints a chief commercial officer. And Onconova Therapeutics boosts its drug development expertise with addition of new CMO, R&D.
You may also be interested in...
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
Board directors appointed at Athersys, Trillium Therapeutics and Viatris
Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead
CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.